A Phase I, Open-label, Ascending Dose Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Endothelin B Agonist, SPI-1620, in Patients With Recurrent or Progressive Carcinoma
Clinical trial NCT00613691 · COMPLETED
Trial details
- NCT number
- NCT00613691
- Sponsor
- Spectrum Pharmaceuticals, Inc
- Status
- COMPLETED
- Phase
- Phase 1
- Study type
- INTERVENTIONAL
- Start date
- 2008-01-01
- Primary completion
- 2012-01-01
- Enrollment
- 36
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.